Featured News

We are delighted to report at the beginning of this calendar year two significant milestones in our ongoing efforts to compel the federal government to treat celiac disease with the seriousness it deserves.  

For the first time ever, access for funding for celiac disease research is being made available through the U.S. DOD Congressionally Directed Medical Research Programs (DOD-CDMRP) Peer Review Medical Research Program Listing.

2023 promises to be a year full of robust research, advocacy, and education efforts on behalf of our patient community.

The American College of Gastroenterology has updated its guidelines for the diagnosis and management of celiac disease, bringing current the recommendations outlined in 2013.

Consider joining the CeDar Rose Study, a remote celiac disease study that will monitor individual gluten tolerance.

The Celiac Disease Foundation is pleased to announce it will provide patient recruitment and eligibility screening for Anokion’s phase 1b/2 clinical trial for KAN-101.

Consider joining the LILY Study, a phase 1 clinical trial for people with celiac disease investigating DONQ52, a new potential celiac disease treatment.

iCureCeliac® is the Foundation’s patient-powered tool that is the single best resource for celiac disease researchers around the world helping to accelerate the search for treatments and a cure.

Digestive Disease Week (DDW), the largest and most important gathering of gastrointestinal researchers in the world, was held in San Diego from May 21-24, 2022.

A recent study found that avoidant/restrictive food intake disorder (ARFID) is common among people with celiac disease.